C. Le Tourneau, et al. SITC 2024 Abstract disponible sur le site du SITC – Télécharger abstract and the poster
Catégorie : publication HomePage
TG7010: a Novel Chimeric Oncolytic Poxvirus Encoding IL-12 with Improved Properties for Systemic Delivery
J. Foloppe, et al. IOVC 2024 Abstract disponible sur le site de l’IOVC – Télécharger abstract and the poster
Transgene présentera un poster sur les données actualisées de TG4050 au SITC 2024
SITC 2024
Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
S. Champiat, et al. ESMO 2024 Abstract disponible sur le site de l’ESMO – Télécharger abstract and the poster
TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment
L.Fend, et al. ESMO 2024 Abstract available on the CICON website – Download the abstract and the poster
TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment
Article disponible en anglais ici sur le site du JITC (The Journal for ImmunoTherapy of Cancer)
Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers
A. Lalanne, et al. AACR 2024 Abstract available on the AACR website – Download the poster Poster Presentation
Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers
C. Le Tourneau, et al.European Journal of Cancer, July 2023 (191)Access the article herePublication
Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma
C. Ottensmeier, et al. ASCO 2023 Abstract available on the ASCO website – Download the abstract and the posterPoster Presentation
Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancers
C. Le Tourneau, et al.ASCO 2023 Abstract available on the ASCO website – Download the abstract and the poster Poster Presentation
